Upadacitinib Demonstrates Higher Rates of Adverse Events Compared with Adalimumab in PsA
Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.
Source: hcplive.com
Gerdr Burmester News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Gerdr Burmester. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Gerdr Burmester Today - Breaking & Trending Today
More Than Half of RA Patients Achieve Remission After Upadacitinib 15 mg
An extension study showed upadacitinib 15 mg and 30 mg for rheumatoid arthritis continues to be favorable, with many patients achieving remission.
Source: hcplive.com
Tofacitinib Shows Similar Safety Profile in PsA, RA Post-Marketing Data
Researchers report on the global real-world safety profile of tofacitinib in psoriatic arthritis.
Source: hcplive.com
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Investegate announcements from Galapagos NV, Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Source: investegate.co.uk
Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission
Source: finanznachrichten.de